Search results
Added:
2 months ago
Presented at the European Society of Cardiology (ESC) Congress 2025, Prof Carolyn Lam (Singapore, UK), Prof Davide Capodanno (Catania, IT), Dr Sneha Shah Jain (Stanford, US) and Prof Jeffrey Weitz (Hamilton, CA) examine the prevalence and challenges of stroke prevention in atrial fibrillation (AF) and after acute coronary syndrome (ACS). The faculty review current treatment guidelines, explore…
View more
Added:
5 days ago
Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview Questions:Can you provide an overview…
View more
Added:
1 year ago
ESC Congress 2024 — No difference in cardiovascular outcomes between invasive and conservative strategies in elderly NSTEMI patients.Principal Investigator, Prof Vijay Kunadian (Newcastle upon Tyne Hospitals NHS Trust, UK) join us in London to discuss the key findings from the SENIOR RITA trial (NCT03052036; Newcastle-upon-Tyne Hospitals NHS Trust).The SENIOR-RITA trial is a multicenter, open…
View more
Added:
2 months ago
Explore the evolving paradigm of lifetime management in TAVI with Dr Mohamed MarwanThis presentation addresses the critical shift from single-procedure focus to comprehensive lifetime planning in TAVI management. As guidelines expand to include patients as young as 65 years old, Dr Marwan examines the unique considerations that arise when treating more active individuals who may require future…
View more
Added:
3 days ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents results from the POLY-HF trial (NCT04633005), evaluating a polypill strategy combining multiple evidence-based medications for heart failure with reduced ejection fraction.This single-center randomized trial enrolled 212 patients with HFrEF (ejection fraction ≤40%) who were not…
View more
Added:
2 months ago
Discover the rapidly evolving therapeutic options transforming outcomes for cardiac amyloidosis patients with Dr Sarah Cuddy.This comprehensive presentation, part of the Cardiomyopathies track, explores the dramatic advances in both TTR and AL amyloidosis treatment over the past decade. Dr Cuddy examines how modern therapeutic approaches have fundamentally shifted survival curves, particularly…
View more
Added:
1 month ago
Navigate the rapidly evolving treatment landscape for hypertrophic cardiomyopathy with Dr Anjali Tiku Owens, a renowned expert in inherited cardiovascular diseases and advanced heart failure.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, explores both established and emerging therapeutic approaches for obstructive and non…
View more
Start date:
Oct 06, 2025
Following the ESC 2025 symposium 'Revolutionising Thrombosis Treatment in ACS, SSP and AF – Bridging the Gaps With Next Generation Anticoagulation Strategies', this live Q&A webinar offers an exclusive chance to continue the conversation.Join Prof Carolyn Lam (Singapore, UK), Prof Jeffrey Weitz (Hamilton, CA) and Dr Sneha Shah Jain (Stanford, US) as they address your questions on stroke…
View more
POTS-associated Conditions and Management Strategies
Video Series
Added:
10 months ago
In this video, Dr Marta Kałużna-Oleksy is joined by Dr Mirvat Alasnag, Dr Shrilla Banerjee and Dr Michal Hawranek to discuss strategies for heart failure management, based on a presentation at the Prevention and Intervention meeting in 2024.The faculty discuss SCAD, MINOCA and holistic approaches to managing these conditions, including lifestyle factors, hypertension and diabetes. They outline…
View more